DE69026837T2 - Transdermales system - Google Patents

Transdermales system

Info

Publication number
DE69026837T2
DE69026837T2 DE69026837T DE69026837T DE69026837T2 DE 69026837 T2 DE69026837 T2 DE 69026837T2 DE 69026837 T DE69026837 T DE 69026837T DE 69026837 T DE69026837 T DE 69026837T DE 69026837 T2 DE69026837 T2 DE 69026837T2
Authority
DE
Germany
Prior art keywords
transdermal system
active substance
dissociation
controlled
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69026837T
Other languages
English (en)
Other versions
DE69026837D1 (de
Inventor
Jens Hansen
Birgitte Moellgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McNeil AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of DE69026837D1 publication Critical patent/DE69026837D1/de
Publication of DE69026837T2 publication Critical patent/DE69026837T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE69026837T 1989-12-21 1990-12-12 Transdermales system Expired - Fee Related DE69026837T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8904296A SE8904296D0 (sv) 1989-12-21 1989-12-21 Transdermal system
PCT/SE1990/000822 WO1991009592A1 (en) 1989-12-21 1990-12-12 Transdermal system

Publications (2)

Publication Number Publication Date
DE69026837D1 DE69026837D1 (de) 1996-06-05
DE69026837T2 true DE69026837T2 (de) 1997-01-02

Family

ID=20377820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69026837T Expired - Fee Related DE69026837T2 (de) 1989-12-21 1990-12-12 Transdermales system

Country Status (11)

Country Link
US (1) US5120546A (de)
EP (1) EP0519926B1 (de)
JP (1) JP3141110B2 (de)
AT (1) ATE137405T1 (de)
AU (1) AU6973591A (de)
DE (1) DE69026837T2 (de)
DK (1) DK0519926T3 (de)
ES (1) ES2086529T3 (de)
GR (1) GR3020436T3 (de)
SE (1) SE8904296D0 (de)
WO (1) WO1991009592A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
DE10357321A1 (de) * 2003-12-05 2005-07-21 Tesa Ag Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
HU212730B (en) * 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733269A (en) * 1996-03-15 1998-03-31 Fuisz Technologies Ltd. Method and kit for positioning transdermal delivery system
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
AU5095698A (en) * 1996-10-25 1998-05-15 Copley Pharmaceutical Inc. Transdermal patch
US6022558A (en) * 1997-07-01 2000-02-08 Hu; Oliver Yoa-Pu Transdermal preparations of oxicams
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6146656A (en) * 1998-01-22 2000-11-14 Nitto Denko Corporation Percutaneous absorption preparation
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
AU759016B2 (en) 1998-10-05 2003-04-03 Penn State Research Foundation, The Compositions and methods for enhancing receptor-mediated cellular internalization
KR100603168B1 (ko) 1998-12-18 2006-07-24 알자 코포레이션 투명한 경피성 니코틴 전달 장치
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6465004B1 (en) * 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
DE10003767A1 (de) * 2000-01-28 2001-10-04 Beiersdorf Ag Hautfreundliches Wirkstoffpflaster zur transdermalen Verabreichung nichtsteroidaler Antirheumatika
KR20030003769A (ko) * 2000-05-31 2003-01-10 니찌방 가부시기가이샤 경피흡수형 스테로이드 외용제
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
US20030206945A1 (en) * 2000-12-20 2003-11-06 Giulio Tarro Sticking plaster for controlled release of natural interferon
DE10141651B4 (de) * 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US6743254B2 (en) * 2002-02-01 2004-06-01 Mentor Corporation Tissue expander with protection against accidental puncture
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
AU2003231571A1 (en) * 2002-04-30 2003-11-17 Mochida Pharmaceutical Co., Ltd. External preparation enhanced in systemic property of vidarabine
US20030215487A1 (en) * 2002-05-17 2003-11-20 Il Yang Pharm Co., Ltd. Republic Of Korea Matrix-type device for the transdermal delivery of testosterone applied to the non-scrotal skin
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
EP2316440A1 (de) * 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermale Dosierungsformen, die eine Wirkstoffkomponente und eine Entgegengesetzt wirksame Komponente an der Distalen seite der Wirkstoffschicht sowie eine Verbindung für Flüssigkeiten zwischen der Oberfläche mit Wirkstoff und dem Antagonisten enthalten
US7323191B2 (en) * 2003-07-28 2008-01-29 Alza Corporation Transdermal warfarin system
JP4160474B2 (ja) * 2003-08-01 2008-10-01 リンテック株式会社 角質改善用積層シート
WO2005044139A2 (en) * 2003-10-28 2005-05-19 Alza Corporation Method and apparatus for reducing the incidence of tobacco use
EP1729746B1 (de) * 2004-03-19 2009-11-18 McNeil AB Mittel für die transdermale verabreichung von nikotin
WO2007016419A2 (en) * 2005-07-29 2007-02-08 The General Hospital Corporation Methods and compositions for reducing skin damage
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
US20080156821A1 (en) * 2006-04-25 2008-07-03 Bradley Stuart Galer Topical preparation dispensers and methods of using the same
US20070248656A1 (en) * 2006-04-25 2007-10-25 Galer Bradley S Topical preparation dispensers and methods of using the same
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
CN101631565A (zh) * 2007-01-17 2010-01-20 德维里克斯股份公司 环糊精制剂
DE102007020799A1 (de) 2007-05-03 2008-11-06 Novosis Ag Transdermales therapeutisches System mit Remifentanil
IE20080661A1 (en) * 2008-08-11 2010-03-03 Bk Pharma Systems Ltd Formulations for a two-phase management of wound healing and dressings incorporating such formulations.
KR101563308B1 (ko) * 2008-11-11 2015-10-26 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 피노셈브린과 사이클로덱스트린 또는 그의 유도체와의 포접 화합물
EP2504039A4 (de) * 2009-11-25 2014-07-02 Univ Loma Linda Med Blutstillender stoff auf chitosanbasis
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
JP5696279B2 (ja) * 2010-12-01 2015-04-08 学校法人自治医科大学 長期徐放型薬剤硬膜外腔留置システム
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
DE102020111668A1 (de) 2020-04-29 2021-11-04 Organoid Technologies Gmbh Naturstoffpad
PL3962455T3 (pl) 2020-05-18 2023-01-16 Orexo Ab Nowa kompozycja farmaceutyczna do dostarczania leku
EP4236921A1 (de) 2021-11-25 2023-09-06 Orexo AB Adrenalin enthaltende pharmazeutische zusammensetzung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
US4661105A (en) * 1981-06-29 1987-04-28 Alza Corporation Medical bandage for administering vasodilator drug
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
EP0241806A1 (de) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Transdermale Zubereitungen mit verzögerter Freisetzung
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
JPH06253662A (ja) * 1993-02-26 1994-09-13 Iseki & Co Ltd 脱穀装置

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
DE10357321A1 (de) * 2003-12-05 2005-07-21 Tesa Ag Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
US7494707B2 (en) 2003-12-05 2009-02-24 Tesa Aktiengesellschaft High-tack adhesive, method of its preparation and the use thereof
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum

Also Published As

Publication number Publication date
JPH05504895A (ja) 1993-07-29
DK0519926T3 (da) 1996-06-17
WO1991009592A1 (en) 1991-07-11
SE8904296D0 (sv) 1989-12-21
JP3141110B2 (ja) 2001-03-05
EP0519926A1 (de) 1992-12-30
GR3020436T3 (en) 1996-10-31
ES2086529T3 (es) 1996-07-01
EP0519926B1 (de) 1996-05-01
ATE137405T1 (de) 1996-05-15
DE69026837D1 (de) 1996-06-05
US5120546A (en) 1992-06-09
AU6973591A (en) 1991-07-24

Similar Documents

Publication Publication Date Title
DE69026837D1 (de) Transdermales system
AR241008A1 (es) Procedimiento para el montaje de un ascensor y el ascensor obtenido por el mismo''
NL300007I1 (nl) Preparaat voor de gereguleerde afgifte van een werkzame stof.
PT92838A (pt) Dispensing devices powered by hydrogel
DE3853420D1 (de) Anrufbearbeitung mit Wechselwirkung.
DE68909691T2 (de) Multischichtkörper zur Abgabe von Duftstoffen.
FI921606A (fi) Mikroperoxidas innehaollande hemopeptid som aktiv komponent.
FI941452A (fi) Yhdisteitä, jotka lisäävät muiden sytotoksisten aineiden kasvaimenvastaista aktiivisuutta
ES2054962T3 (es) Agentes plaguicidas.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
NO880348D0 (no) Opprettningsanordning for bilkarosserier.
NO902626D0 (no) Fremgangsmaate for stabilisering av biologisk aktive forbindelser immobilisert paa faste faser.
IT1228673B (it) Dispositivo per la compensazione di tolleranze di posizione.
NO901605L (no) Fremgangsmaate for stabilisering av polyolefiner.
IT216683Z2 (it) Corpo di bobina riutilizzabile.
SE8803935L (sv) Laekemedelskomposition
DK162999C (da) Imidazoquinazolinforbindelse samt fremgangsmaade til fremstilling deraf
IT8320600A0 (it) Composizione per un'applicazione topica contenente, come sostanza attiva sull'elasticia', la morbidezza della pelle tiamorfolinone oppure uno dei suoi derivati.
DK376082A (da) Insekticid
ZA909624B (en) Transdermal system for administering pharmacological compounds under ph-control
DE68908858T2 (de) Sandelholzriechstoffe.
NO903111D0 (no) Fremgangsmaate til fremstilling av antiinfeksjonsmidler.
FR2618707B1 (fr) Dispositif de retournement de pieces, notamment de pieces de carrosserie
NO163375C (no) Fremgangsmaate for forbedring av injeksjonsegenskapene tilen vandig heteropolysakkaridopploesning.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER HEALTH AB, STOCKHOLM, SE

8327 Change in the person/name/address of the patent owner

Owner name: MCNEIL AB, HELSINBORG, SE

8328 Change in the person/name/address of the agent

Representative=s name: PATENT- UND RECHTSANWAELTE BARDEHLE, PAGENBERG, DO

8339 Ceased/non-payment of the annual fee